UNIQURE N.V. news, videos and press releases - Page 3
For more news please use our advanced search feature.
UNIQURE N.V. - More news...
UNIQURE N.V. - More news...
- uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
- uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
- uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
- uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
- uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure to Participate in Upcoming Industry Conferences in November
- uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
- uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
- uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
- uniQure to Participate in Multiple Upcoming Industry Conferences in October
- uniQure to Participate in Multiple Upcoming Industry Conferences in September
- uniQure Announces Completion of Additional Patient Procedures Following Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure Announces Second Quarter 2021 Financial Results and Highlights Recent Company Progress
- uniQure Announces Presentations at Upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress
- uniQure Announces Positive 52-Week Clinical Data from HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B and Provides Regulatory Update
- uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
- uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- UPDATE -- uniQure to Participate in Multiple Upcoming Industry Conferences in June
- uniQure to Participate in Multiple Upcoming Industry Conferences in June
- uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
- uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-existing Antibodies to AAV5 Vector
- uniQure Announces First Quarter 2021 Financial Results and Highlights Recent Company Progress
- uniQure announces closing of commercialization and license agreement with CSL Behring
- uniQure to Participate in Multiple Upcoming Industry Conferences in May
- uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program
- uniQure Announces Publications of Preclinical Data for AMT-130 in Huntington’s Disease Showing Safety of Administration in NHPs and Widespread Long-Term HTT-Lowering in the Brain
- uniQure Announces Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
